SNORD105B: SNORD105B is a small nucleolar RNA (snoRNA) that has been implicated in various cancers, including B-cell lymphocytic leukemia (CLL), ovarian cancer, gastric cancer, and colon adenocarcinoma. It has been found to be upregulated in proliferating normal B-cells and CLL cells, suggesting its functional relevance in cell proliferation [PMC9219770]. In ovarian cancer, SNORD105B is part of a signature of nine snoRNAs that may serve as prognostic and therapeutic targets [PMC10050728]. In gastric cancer, SNORD105B is overexpressed and promotes tumorigenesis through the ALDOA/C-Myc pathway [PMC6584411]. It has also been associated with ER-negative tumors and triple-negative breast cancer (TNBC), as well as poorer outcomes [PMC9803687]. SNORD105B has been shown to bind to ALDOA and upregulate the expression of C-myc in gastric cancer [PMC9098889]. Additionally, SNORD105B is downregulated in tumor tissues compared to normal tissues in gastric cancer [PMC9119353]. Knockdown of SNORD105B attenuates the growth of gastric cancer cells [PMC8677010]. Overall, these findings suggest that SNORD105B plays a role in cell proliferation and tumorigenesis through various pathways.